Woodward Drug Patent Portfolio
Woodward owns 1 orange book drug protected by 6 US patents Given below is the list of Woodward's drug patents along with their expiration dates.
Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
---|---|---|---|
US7358366 | Thiazolidinedione derivative and its use as antidiabetic | 19 Oct, 2020 | Expired |
US7358366 | Thiazolidinedione derivative and its use as antidiabetic | 19 Apr, 2020 | Expired |
US6288095 | Compounds | 11 Aug, 2017 | Expired |
US6288095 | Compounds | 11 Feb, 2017 | Expired |
US5741803 | Substituted thiazolidinedionle derivatives | 21 Oct, 2015 | Expired |
US5741803 | Substituted thiazolidinedionle derivatives | 21 Apr, 2015 | Expired |
Latest Legal Activities on Woodward's Drug Patents
Given below is the list of recent legal activities going on the following drug patents of Woodward.
Activity | Date | Patent Number |
---|---|---|
![]() | ||
Expire Patent
Critical
| 14 May, 2012 | US7358366 |
Recordation of Patent Grant Mailed
Critical
| 15 Apr, 2008 | US7358366 |
Patent Issue Date Used in PTA Calculation
Critical
| 15 Apr, 2008 | US7358366 |
Issue Notification Mailed
Critical
| 26 Mar, 2008 | US7358366 |
Dispatch to FDC | 17 Mar, 2008 | US7358366 |
Response to Amendment under Rule 312
Critical
| 12 Mar, 2008 | US7358366 |
Mail Response to 312 Amendment (PTO-271)
Critical
| 12 Mar, 2008 | US7358366 |
Application Is Considered Ready for Issue
Critical
| 05 Mar, 2008 | US7358366 |
Amendment after Notice of Allowance (Rule 312)
Critical
| 22 Feb, 2008 | US7358366 |
Issue Fee Payment Received
Critical
| 22 Feb, 2008 | US7358366 |
Issue Fee Payment Verified
Critical
| 22 Feb, 2008 | US7358366 |
Mail Notice of Allowance
Critical
| 23 Nov, 2007 | US7358366 |
Notice of Allowance Data Verification Completed
Critical
| 20 Nov, 2007 | US7358366 |
Date Forwarded to Examiner | 17 Nov, 2007 | US7358366 |
Response after Non-Final Action
Critical
| 05 Oct, 2007 | US7358366 |
Woodward's Family Patents

Woodward Drug List
Given below is the complete list of Woodward's drugs and the patents protecting them.
1. Avandia
Avandia is protected by 6 patents, out of which all have expired. Check out its patent list below.
Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
---|---|---|---|
US7358366
(Pediatric)
| Thiazolidinedione derivative and its use as antidiabetic |
19 Oct, 2020
(4 years ago)
| Expired |
US7358366 | Thiazolidinedione derivative and its use as antidiabetic |
19 Apr, 2020
(4 years ago)
| Expired |
US6288095
(Pediatric)
| Compounds |
11 Aug, 2017
(7 years ago)
| Expired |
US6288095 | Compounds |
11 Feb, 2017
(8 years ago)
| Expired |
US5741803
(Pediatric)
| Substituted thiazolidinedionle derivatives |
21 Oct, 2015
(9 years ago)
| Expired |
US5741803 | Substituted thiazolidinedionle derivatives |
21 Apr, 2015
(9 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Avandia's drug page
Explore Our Curated Drug Screens
Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List